

18 September 2017

Dear Shareholder,

## Renounceable entitlement offer to raise up to approximately \$1.593 million

Analytica Limited (**Company**) today announced that it is undertaking a renounceable pro-rata entitlement offer to eligible shareholders to raise approximately \$1.593 million (before offer costs) (**Entitlement Offer**).

The Entitlement Offer comprises:

- (a) (**New shares**) 1 new share for every 8 existing Shares held at 7.00pm on Thursday, 21 September 2017 (**Record Date**) at an offer price of 0.5 cents per new share; and
- (b) (**Attaching Options**) for every share allotted under the Entitlement Offer, the applicant will receive 2 options comprising:
  - (i) 1 option expiring on 31 January 2018 and exercisable at 0.5 cents; and
  - (ii) 1 option expiring on 31 May 2018 and exercisable at 0.5 cents,(together called the **Attaching Options**). No application will be made for the Attaching Options to be listed on ASX.

### Eligible Shareholders

The Entitlement Offer will be offered to all shareholders of the Company with a registered address in Australia or New Zealand as at the Record Date (**Eligible Shareholders**). Shareholders that are not Eligible Shareholders are **Ineligible Shareholders**.

The Company regrets that, having considered the number of shareholders with registered addresses outside Australia and New Zealand, the number and value of the shareholdings held by Ineligible Shareholders, and the costs of complying with the laws and any requirements of any regulatory authority in each applicable jurisdiction, it will not extend the Entitlement Offer to Ineligible Shareholders.

### Additional Shares

Eligible Shareholders may also apply for Additional Shares (which are shares that are not taken up by Eligible Shareholders) in excess of their entitlement. The allocation of Additional Shares will be limited to the number of shortfall shares (if any) and will be at the discretion of the Directors. Eligible Shareholders who apply for Additional Shares may receive fewer Additional Shares than the number applied for or none at all. Successful applicants for Additional Shares will be entitled to the Attaching Options.

### Use of funds

The capital raised will be used to fund development costs in connection with the PeriCoach™ System and general working capital requirements. There is no minimum amount sought to be raised under the Entitlement Offer and the new shares and Attaching Options may be issued in respect of applications irrespective of the total level of subscriptions made.

### Entitlements

Entitlements in respect of new shares and Attaching Options will be rounded down to the nearest whole number and holdings on different registers or sub-registers will not be aggregated to calculate entitlements.



## Rights trading

The entitlements under the Entitlement Offer are renounceable. Accordingly, you may trade on ASX your rights to subscribe for new shares and Attaching Options under the Entitlement Offer to any other party during the rights trading period which commences on Tuesday, 26 September 2017 and ends on Thursday, 5 October 2017. If you do not take up or trade your entitlements to the shares and Attaching Options under the Entitlement Offer by the Closing Date (Thursday, 5 October 2017), the offer to you will lapse.

## Company's capital structure pro-forma

The table below provides a pro-forma capital structure of the Company after completion of the Offers assuming that:

- (a) all of the entitlements are taken up; and
- (b) no options are exercised prior to the Record Date;
- (c) no new shares are issued by the Company.

Please note that the actual outcome of the Entitlement Offer may differ.

Share capital – full subscription	
Shares currently on issue	2,549,136,332
Plus: new shares issued under the Entitlement Offer	318,642,042
<b>Total issued share capital on completion of Entitlement Offer (undiluted)</b>	<b>2,867,778,374</b>
Options on issue	346,488,860
Plus: Attaching Options	637,284,084
<b>Fully diluted share capital on completion of Entitlement Offer*</b>	<b>3,851,551,318</b>

\* Assuming all options are exercised.

## Further information

The Offers are being made under a Prospectus dated 18 September 2017 which was lodged with ASIC on that date. Shareholder approval is not required for the issue of new shares or Attaching Options under the Entitlement Offer. New shares issued will rank equally in all respects with the fully paid ordinary shares already on issue and the Company has applied for the quotation of the new shares on ASX.

Further details of the Entitlement Offer, including details on the use of proceeds and the expenses associated with conducting the Entitlement Offer will be contained in the Prospectus. The Prospectus containing the Entitlement Offer will be sent to Eligible Shareholders on or about Tuesday, 26 September 2017 accompanied by personalised entitlement and acceptance forms to subscribe for new shares under the Entitlement Offer. A copy of the Prospectus will be available on the ASX website at [www.asx.com.au](http://www.asx.com.au) and the Company's website at [www.analyticamedical.com](http://www.analyticamedical.com).



## Important dates

Event	Date
Prospectus Lodged	Monday, 18 September 2017
Existing shares quoted on an 'ex-rights' basis, Rights Trading commences	Wednesday, 20 September 2017
Record Date	Thursday, 21 September 2017
Entitlement Offer opens Prospectus dispatched	Tuesday, 26 September 2017
Rights trading ends	Thursday, 5 October 2017
Entitlement Offer closes	5pm Sydney Time, Thursday, 12 October 2017
Announcement of shortfall (if any) under the Entitlement Offer	Tuesday, 17 October 2017
Allotment date of new shares and options issued under the Entitlement Offer	Thursday, 19 October 2017
Dispatch of holding statements for New Shares issued under the Entitlement Offer. Normal trading of New Shares issued under the Entitlement Offer	Friday, 20 October 2017

The timetable is subject to change and the Company reserves the right to withdraw or vary the timetable for the Offers without notice. In particular, the Company reserves the right to extend the closing date for the Entitlement Offer, to accept late applications whether generally or in particular cases or to withdraw the Offers without prior notice.

On behalf of the Directors and Management I thank you for your ongoing support of the Company.

Yours sincerely

Dr Michael Monsour

Chairman



For more information, please contact: [investorrelations@analyticamedical.com](mailto:investorrelations@analyticamedical.com)

For more information about the PeriCoach System, visit: [www.PeriCoach.com](http://www.PeriCoach.com)

For more information about Analytica, visit [www.AnalyticaMedical.com](http://www.AnalyticaMedical.com)

Follow us on:



### About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from [pericoach.com](http://pericoach.com) in Australia and New Zealand, UK and Ireland, and in the USA.

